Abstract: Food products are provided in which microbial protein sources, such as single cell protein or protein hydrolysis products, are incorporated. Artificial meat products are provided that include microbial protein in place of animal protein.

Abstract: Structured food compositions, such as meat analogue compositions, which include protein products from microorganisms, such as microorganism-derived protein hydrolysates, are described. Methods of making such products are also described.

Abstract: Food products are provided in which microbial protein sources, such as single cell protein or protein hydrolysis products, are incorporated. Artificial meat products are provided that include microbial protein in place of animal protein.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Bioreactors and methods for growing a chemoautotrophic culture of a microorganism, such as a hydrogen-oxidizing or carbon monoxide-oxidizing microorganism, are provided. The bioreactors and methods provide for enhanced growth and productivity of microorganisms that use gaseous sources of carbon and energy and provide an environment for carbon fixing to produce organic molecules of interest and/or biomass. The present bioreactors and methods achieve enhanced growth with respect to cell density, culture duration and/or growth rate, while maintaining safe operating conditions.

Abstract: The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least one, preferably at least two, attachment point(s) or conjugation site(s). In particular, the technology provides a molecule comprising at least one protein-based building block, wherein the at least one protein-based building block: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg/ml or more, measured in an aqueous solution at room temperature; and does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5×10?4 mol/litre.

Abstract: Food products are provided in which microbial protein sources, such as single cell protein or protein hydrolysis products, are incorporated, and from which endotoxins, and optionally nucleic acids, have been reduced or removed.

Abstract: Bioreactors and methods for growing a chemoautotrophic culture of a microorganism, such as a hydrogen-oxidizing or carbon monoxide-oxidizing microorganism, are provided. The bioreactors and methods provide for enhanced growth and productivity of microorganisms that use gaseous sources of carbon and energy and provide an environment for carbon fixing to produce organic molecules of interest and/or biomass. The present bioreactors and methods achieve enhanced growth with respect to cell density, culture duration and/or growth rate, while maintaining safe operating conditions.

Abstract: Systems, methods, and devices for a method for determining a recommended cycling event. In one embodiment, a method includes receiving ride data associated with a rider of a bicycle and collected by a plurality of sensors during a ride on a trail, determining a recommended cycling event for the rider by processing the ride data through an AI model trained with previously received ride data collected during a plurality of rides on a plurality of trails, and providing the recommended cycling event to a user device associated with the rider.

Abstract: Systems, methods, and devices for determining a cycling simulation of a trail ride. In one embodiment, a method includes receiving ride data collected by a plurality of sensors during a ride on a trail. The ride data is segmented into a plurality of time segments. The plurality of sensors are mounted to a bicycle or a rider of the bicycle. The method further includes determining a resistance model for the rider and the ride by determining a resistance variable for each time segment based on the received ride data and determining a power variable necessary to overcome each of the resistance variable at each respective time segment based on a plurality of user specific variables. The method further includes determining a cycling simulation of the ride based on the resistance model and providing the cycling simulation of the ride to a smart trainer device.

Abstract: Optionally, a plurality of spacers 228 is arranged between the planar surface 120 of the interfacing arrangement 114 (or the top horizontal arm) and the seat arrangement 102, for permanently raising the seat arrangement 102 with respect to the interfacing arrangement 114. The spacers 228 can be implemented as rectangular or cylindrical solid blocks that can be fabricated from plastics materials, metals, metal alloys, polymers, ceramics, wood, composites and so forth. The spacers 228 can be fixed between the seat arrangement 102 and the top planar surface 120 of the top horizontal arm of the interfacing arrangement 114 such that height of the seat arrangement 102 relative to the footrest arrangement 116 is raised. For example, a plurality of metallic spacers is fixed between the seat arrangement 102 and the interface arrangement by a technician such as by welding the metallic spacers between the seat arrangement 102 and the interface arrangement.

Abstract: Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK modulator (e.g., an IRAK-4 degrader) with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK modulator in combination with a gene therapy agent.

Abstract: Provided herein are methods for enhancing gene therapy in an individual by administering an IRAK degrader with the gene therapy to suppress innate immunity to the gene therapy. In some embodiments, the gene therapy uses an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a Herpes simplex virus (HSV) vector or a lipid nanoparticle. Also provided herein are methods for selecting an individual for treatment with an IRAK degrader in combination with a gene therapy agent.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.